International Myeloma Foundation Gears Up for March, Myeloma Action Month
To raise awareness of multiple myeloma and efforts to cure it, the International Myeloma Foundation (IMF) is gearing up for the start of Myeloma…
Myeloma
Multiple Myeloma Research Foundation Makes Changes in Leadership to Advance Precision Medicine
The Multiple Myeloma Research Foundation (MMRF) is growing and adjusting its executive team, with a focus on improving multiple myeloma patient outcomes and advancing…
Partners to Develop and Market TNB-383B Antibody for Multiple Myeloma
The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new…
Split Dosing of Darzalex Over Consecutive Days Approved by FDA for Multiple Myeloma Patients
The U.S. Food and Drug Administration has approved a new dosing regimen for the multiple myeloma treatment Darzalex (daratumumab), allowing doctors to split the first…
$75M Gift to Establish Center for Blood Cancers at NYU Langone Health Center
Owing to an anonymous $75 million gift, New York University (NYU) Langone Health and its Laura and Isaac Perlmutter Cancer Center will establish…
Real-world Data Supports Use of Oral Triple Combination in Treating Advanced Multiple Myeloma, Study Finds
Real world data from multiple myeloma patients in Hungary supports the use of a triple combination regimen — Ninlaro (ixazomib), Revlimid (lenalidomide), and…
Isatuximab Extends Time Without Cancer Progression in Phase 3 Trial of Multiple Myeloma
Adding isatuximab to a standard of care treatment of Pomalyst (pomalidomide) and low-dose dexamethasone prolonged the time without cancer progression in adults with relapsed…
Thalidomide at 100 mg Shows Benefits as Maintenance Therapy in Multiple Myeloma Patients in Trial
A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma…
Donation Will Establish Center for Multiple Myeloma Research in UK
Thanks to a £10 million donation (about $13,000,000), Imperial College London will establish a center for multiple myeloma research at the institution’s Hammersmith…
Measuring Blood Vessel Activity May Predict Multiple Myeloma Prognosis
A panel of blood markers that identifies tumors with more active blood vessels may help stratify multiple myeloma patients according to their risk, a study found.
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment